At the end of the treatment evaluation, they also looked at progression ... Depth of remission is key in myeloma because it ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...